Immediate visibility for accelerated federal procurement. We position AI diagnostics, novel therapeutics, and MedTech innovations for rapid agency adoption — turning sole-source justifications into signed contracts across VA, DoD, IHS, and beyond.
Most MedTech innovators build FDA-cleared, clinically validated solutions — then stall at the federal door. Procurement cycles are opaque, contracting vehicles are complex, and without strategic positioning, your technology never reaches the clinicians who need it.
The vendor who frames the category first becomes the default option. If you’re not shaping that narrative, your competitors are shaping it for you.
A proven four-phase approach that takes your innovation from invisible to orderable across federal supply chains.
01We align your technology with top federal priorities — clinician shortage mitigation, rural access mandates, readiness, and value-based care.
02Targeted outreach to clinical leads, program managers, and acquisition decision-makers across VA, DoD, IHS, HRSA, and beyond.
03We activate the fastest procurement channels — 8153 HCR, ECAT, DAPA, GPC, OTA, BAAs — so your technology becomes orderable.
04Coordinating with clinicians, logistics chiefs, and contracting officers to support pilots and multi-site adoption from day one.
Anonymized engagements illustrating how our framework accelerates federal procurement for different MedTech categories.
An AI-powered diagnostic system capable of delivering clinical-grade results without specialist interpretation — operated entirely by technicians at the point of care. No competitor offered equivalent autonomous capability, creating a clear basis for non-substitutable classification under FAR 6.302-1.
Established non-substitutable capability positioning enabling direct awards without competitive bidding
Strategic alignment across VA, DoD, IHS, HRSA, CMS, BOP, and USPHS
Rapid acquisition pathways identified to make technology orderable within weeks
Sole-source positioning enabled the innovator to set all parameters
A ruggedized, field-deployable diagnostic platform designed for austere environments — military forward operating bases, disaster response zones, and remote tribal health facilities. The system’s ability to operate without infrastructure or specialist personnel made it uniquely suited for federal missions.
Positioned against DoD deployment health, FEMA disaster readiness, and IHS rural access gaps
Identified opportunities that bypassed traditional procurement timelines
Connected with OASIS+ prime contractors for rapid subcontracting
Phased evaluation approach with clinical champions at target agencies
An FDA-cleared imaging system offering real-time surgical guidance with capabilities unavailable through legacy devices. Despite clear clinical superiority, the company had zero federal visibility and no procurement vehicle. We built the entire federal go-to-market strategy from scratch.
Built capability statements and procurement-ready messaging for VA and DoD
Activated VA-specific procurement channels for direct ordering
Identified expiring contracts for competitive replacement positioning
Connected with surgical chiefs across target VISNs
We work with innovators who have breakthrough technology and need a strategic partner to navigate the federal market.
Autonomous platforms, computer vision, and AI clinical decision support seeking federal deployment.
Breakthrough treatments and biologics ready for federal formulary adoption.
Portable trauma systems and disaster response tech for FEMA, DHS, and DoD.
FDA-cleared imaging and surgical tools for federal health networks.
Connected health and remote monitoring for VA, DoD, and population health.
Biodetection and surveillance aligned with BARDA, HHS, and preparedness.
Robotic Surgery
Genomics
Advanced Imaging
AI Screening
Biotech Analysis
Clinical ResearchWe navigate the full spectrum of federal procurement vehicles to find the fastest route for your technology.
We had an FDA-cleared product and strong clinical data but no idea how to approach the federal market. Within weeks of engaging OLV, we had a sole-source strategy, a clear acquisition pathway, and introductions to the right people at VA.
The federal procurement landscape was completely opaque to us. Walt didn’t just explain it — he built the entire positioning strategy, wrote our capability statement, and mapped the specific contracting vehicles we needed. We went from invisible to orderable.
What set OLV apart was the depth of knowledge. They understood both the science behind our technology and the procurement language agencies need to hear. That translation is what most consultants can’t do.
A structured engagement designed to move fast and deliver measurable positioning within weeks.
A 15-minute introductory call to assess your technology, discuss federal goals, and determine fit. No cost, no commitment.
We analyze your competitive positioning under FAR, identify highest-value agency targets, and map the fastest procurement pathways.
We develop procurement-ready messaging, build capability statements, and begin targeted outreach to clinical leads and contracting officers.
We activate procurement channels, coordinate pilot evaluations, establish teaming partnerships, and build clinical demand.
Continued tracking of recompetes, buying cycles, and new agency opportunities as your federal presence expands.
Walt founded OLV BioMed at the intersection of biomedical innovation and federal acquisition strategy. With a career spanning MRI research, biologics, diagnostics, and public health resilience, he brings rare dual fluency — speaking the language of breakthrough science and the language of federal procurement with equal precision. His approach: position your innovation as the only option that meets the agency’s mission need, then activate the fastest acquisition pathway to get it deployed.
We start with a free 15-minute strategy briefing to understand your technology and federal goals. If there’s a fit, we propose a structured engagement that typically begins with a federal landscape assessment, sole-source analysis, and initial positioning — with active outreach and procurement activation following in the first weeks.
The initial positioning work — competitive analysis, sole-source justification development, procurement-ready messaging, and targeted outreach — is what accelerates your federal visibility and lets us set procurement specifications in your favor before larger companies define the parameters. That foundational work creates the traction that drives everything else.
Visibility and acquisition pathways can be activated within weeks. Many clients see meaningful federal traction — active conversations with agency decision-makers, procurement channel activation, or pilot program initiation — within the first 30–60 days.
Under FAR 6.302-1, if your technology offers a capability that no other product can substitute, agencies can award contracts directly to you without full and open competition. You control the cost, delivery schedule, and performance specifications. Most breakthrough MedTech companies don’t realize they qualify. We assess eligibility as part of the initial engagement.
No. Many of our clients start with zero federal presence. We handle the full setup: establishing visibility, identifying procurement pathways, building teaming relationships with established contractors, and positioning your technology for the fastest available acquisition channels.
We work best with MedTech companies, biotech startups, and researchers who have a validated, differentiated technology — typically FDA-cleared or near clearance — and want to enter or expand within federal health markets. If your innovation genuinely advances the standard of care and you’re ready to invest in strategic federal positioning, we’re a strong fit.
Book a 15-minute strategy briefing. We’ll assess your sole-source eligibility, map your agency alignment, and show you how to achieve immediate federal visibility for accelerated procurement.
☎ 310.774.1527 ✉ info@olvbiomed.com